Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: An 8-year retrospective cohort study

Leslie L. Clark, MS,a,b John S. Ikonomidis, MD, PhD,a Fred A. Crawford, Jr, MD,a Arthur Crumbley III, MD,a John M. Kratz, MD,a Martha R. Stroud, MS,a Robert F. Woolson, PhD,b James J. Bruce, MS,a Joyce S. Nicholas, PhD,b Daniel T. Lackland, DrPH,b Michael R. Zile, MD,c and Francis G. Spinale, MD, PhD\(^a\)

**Background:** Cardiac surgical procedures can be associated with significant morbidity and mortality. Recently, it has been recognized that statins might induce multiple biologic effects independent of lipid lowering that could potentially ameliorate adverse surgical outcomes. Accordingly, this study tested the central hypothesis that pretreatment with statins before cardiac surgery would reduce adverse postoperative surgical outcomes.

**Methods:** Demographic and outcomes data were collected retrospectively for 3829 patients admitted for planned cardiac surgery between February 1994 and December 2002. Statin pretreatment occurred in 1044 patients who were comparable with non–statin-pretreated (n = 2785) patients with regard to sex, race, and age. Primary outcomes examined included postoperative mortality (30-day) and a composite morbidity variable.

**Results:** The odds of experiencing 30-day mortality and morbidity were significantly less in the statin-pretreated group, with unadjusted odds ratios of 0.43 (95% confidence interval [CI], 0.28-0.66) and 0.72 (95% CI, 0.61-0.86), respectively. Risk-adjusted odds ratios for mortality and morbidity were 0.55 (95% CI, 0.32-0.93) and 0.76 (95% CI, 0.62-0.94), respectively, by using a logistic regression model and 0.51 (95% CI, 0.27-0.94) and 0.71 (95% CI, 0.55-0.92), respectively, in the propensity-matched model, demonstrating significant reductions in 30-day morbidity and mortality. In a subsample of patients undergoing valve-only surgery (n = 716), fewer valve-only patients treated with statins experienced mortality, although these results were not statistically significant (1.96% vs 7.5%).

**Conclusions:** These findings indicate that statin pretreatment before cardiac surgery confers a protective effect with respect to postoperative outcomes.

C

Common cardiovascular surgical procedures include coronary artery bypass grafting (CABG), as well as valve repair and replacement. Although advancements in surgical technique and postoperative care have resulted in decreasing mortality and morbidity rates for these procedures,1,2 significant complications still occur. Thus identifying pretreatment strategies, such as pharmacologic interventions, that would favorably affect morbidity and mortality after surgical intervention remains an area of significant clinical interest.

A class of pharmacologic compounds that have stimulated significant interest with respect to the prevention of cardiovascular events are the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins).3-6 For example, the Heart Protection Study, a randomized placebo-controlled trial of more than 20,000 pa-
patients, conclusively demonstrated the ability of statins to reduce major cardiovascular events. Of note, this past study demonstrated that patients with normal baseline cholesterol levels also received as much benefit from statin therapy as those with increased low-density lipoprotein (LDL) cholesterol levels. In addition to other in vitro and in vivo studies, this report suggested that statins modify a number of cellular and extracellular processes that might be independent of direct lipid lowering.\textsuperscript{7,8} For instance, past studies have suggested that statins might have a beneficial effect on endothelial function in the context of hypertensive heart disease and diabetes.\textsuperscript{9-11} Other studies have suggested that statins might modify the release of biologically active molecules (eg, tumor necrosis factor α) during and after myocardial ischemia.\textsuperscript{12} In light of these pleiotropic effects, it has been postulated that statin treatment might have beneficial effects in the context of cardiac surgery.\textsuperscript{13,14} Other studies have identified that statin treatment after CABG might favorably modify long-term morbidity and mortality.\textsuperscript{15,16} Accordingly, the present study was designed to test the central hypothesis that a significant risk reduction with respect to major early postoperative events would occur in patients receiving statin treatment preoperatively compared with those patients without statin treatment undergoing cardiac surgery. Although the penetrance of statin treatment in patients with coronary artery disease has increased over the past decade, a relatively high percentage of patients present for cardiac surgery without a prior history of statin treatment. In view of that, we conducted a retrospective study using logistic regression modeling and propensity score methodology to determine the effect of statin pretreatment on 30-day mortality and morbidity after cardiac surgery.

**Methods**

**Study Design**

Since 1993, all patients undergoing cardiac surgery at the Medical University of South Carolina have had their demographic and operative data entered into a registry. Preoperative use of statins in this cohort of surgical patients increased from less than 20% before 1997 to more than 60% in 2000. The availability of these demographic, operative, and medication data allowed a retrospective evaluation of outcomes for patients treated with statins before surgical intervention versus those without while controlling for other potential confounding variables. This retrospective study was approved by the Institutional Review Board of the Medical University of South Carolina and conformed to all institutional review board and Health Insurance Portability and Accountability Act requirements.

**Patient Population**

Patients included in the cohort were 18 years of age or older and presented for nonemergent CABG, valve replacement, and/or valve repair surgery requiring cardiopulmonary bypass during the study period (1994-2002). Any patient presenting for operations involving congenital heart conditions were excluded from this analysis. The study cohort consisted of 3829 patients. Statin pre-treatment occurred in 1044 patients.

**Study Data**

The surgery database used in this study was a complete patient database containing demographics, patient history, medical record information, intraoperative data, and postoperative outcome data. It mirrored the template for the current registry maintained nationally by the Society of Thoracic Surgeons.\textsuperscript{17} This surgical database was merged with the hospital pharmacy database in which all admission and discharge medications are recorded for each patient.

**Outcome Measures**

All outcomes were prespecified. Fatal and nonfatal outcomes were defined as follows: mortality occurring operatively or in the 30-day period postoperatively; myocardial infarction (MI); stroke or cerebrovascular event; hemodynamic collapse; reoperation; or a composite morbidity variable that included the occurrence of any of the morbidity outcomes. Outcomes were adjudicated by all attending cardiothoracic surgeons and intensivists at a weekly surgical morbidity and mortality conference.

**Variable Selection**

The variables analyzed included demographic variables; preoperative, intraoperative, and postoperative data; and medication data. Dichotomous and categoric variables included variables such as race and sex and variables indicating the type of surgical procedure (eg, isolated CABG, CABG with valve repair, and isolated valve repair), as well as the presence or absence of comorbidities. Continuous variables measured were age and body surface area. Variable selection for the logistic model initially involved prespecification of the model by using clinician input for relevant covariates, as well as a literature review of predictive mortality and morbidity models in cardiac surgery.\textsuperscript{18-20} Variables selected for inclusion in the model included patient age, sex, race, preexisting comorbidities, type of cardiac procedure, previous cardiac surgery, ejection fraction, and New York Heart Association class. In addition, predictor variables that were significant at a 2-tailed \( P \) value of less than .15 in univariate analyses were entered into the full model.

**Data Analysis**

Baseline demographics for patients who received statin treatment were compared with those of patients who had not received statin treatment. \( \chi^2 \) Tests were used to determine differences among treated and nontreated patients for categoric variables. The Wilcoxon rank sum test and \( t \) tests were used to compare the 2 groups for continuous variables. Complete data were available on out-

---

**Abbreviations and Acronyms**

- CABG  = coronary artery bypass grafting
- CI  = confidence interval
- LDL  = low-density lipoprotein
- MI  = myocardial infarction
come variables and statin use for all patients. Complete covariate data were available for 3409 patients.

The unadjusted effects of statin use on 30-day morbidity and mortality were assessed by using logistic regression analysis. Risk-adjusted comparisons were made by using multivariable logistic regression models after adjustment for preoperative patient risk factors. In addition, a second method of adjustment using matching on propensity scores was used. Conditional logistic regression was used to analyze these matched pairs and determine the effect of statin treatment on morbidity and mortality. After matching on propensity score, there were no significant differences between the 2 groups.

Propensity Score Development
This study followed a retrospective and nonrandomized design. Therefore there was no control over which patients received statin treatment before surgical intervention versus those who did not. Issues of selection bias and confounding were addressed through the use of a propensity score, a statistical strategy introduced by Rubin and Rosenbaum as a means of addressing the bias that exists in observational studies.21,22 Multiple logistic regression was used in this study to construct propensity scores for statin use. Patients from the statin-treated and statin-untreated groups were then matched on propensity scores, and logistic regression was used to determine the effect of statin treatment on morbidity and mortality.

Results
The study population was drawn from patients undergoing elective cardiac surgery during the period from 1994 through 2002. The use of preoperative statins increased from less than 20% in the initial year of this study to more than 60% in the final year of this study ($P < .001$ for time trend).

Table 1 delineates the type and dose of statin in the statin-treated group. No differences in mortality or morbidity outcomes were observed by type of statin used.

Table 2 presents the overall clinical characteristics for patients treated and not treated with statins. Age and sex distributions were similar in both groups. Body surface area was significantly greater in the statin-treated group. This group was also more likely to have had a previous MI ($P = .0007$) or to be diabetic ($P < .002$), hypertensive ($P < .001$), or hypercholesterolemic ($P < .001$).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Not treated (n = 2785)</th>
<th>Statin treated (n = 1044)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>63.39 ± 12.55</td>
<td>63.18 ± 11.2</td>
<td>.64</td>
</tr>
<tr>
<td>Body surface area</td>
<td>1.93 ± 0.33</td>
<td>1.96 ± 0.22</td>
<td>.007</td>
</tr>
<tr>
<td>Male, %</td>
<td>66.5</td>
<td>66.85</td>
<td>0.836</td>
</tr>
<tr>
<td>Risk factors–comorbidities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current smoker, %</td>
<td>58.71</td>
<td>58.27</td>
<td>.805</td>
</tr>
<tr>
<td>Hypertensive, %</td>
<td>67.02</td>
<td>75.78</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Diabetes, %</td>
<td>28.32</td>
<td>33.33</td>
<td>.002</td>
</tr>
<tr>
<td>Hypercholesterolemia, %</td>
<td>37.95</td>
<td>79.79</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Renal failure, %</td>
<td>6.78</td>
<td>6.63</td>
<td>.865</td>
</tr>
<tr>
<td>NYHA class IV, %</td>
<td>34.53</td>
<td>32.06</td>
<td>.143</td>
</tr>
<tr>
<td>Previous MI, %</td>
<td>37.32</td>
<td>52.81</td>
<td>.000</td>
</tr>
<tr>
<td>Cerebrovascular disease, %</td>
<td>13.91</td>
<td>15.24</td>
<td>.293</td>
</tr>
<tr>
<td>Peripheral vascular disease, %</td>
<td>15.42</td>
<td>15.64</td>
<td>.863</td>
</tr>
<tr>
<td>Immunosuppressive treatment, %</td>
<td>2.09</td>
<td>2.12</td>
<td>.968</td>
</tr>
<tr>
<td>Preoperative use of intra-aortic balloon pump, %</td>
<td>3.48</td>
<td>2.9</td>
<td>.264</td>
</tr>
</tbody>
</table>

NYHA, New York Heart Association; MI, myocardial infarction.
Use of other medications before surgical intervention also differed between the 2 groups. The statin-treated group had a higher percentage of patients treated with β-adrenergic blockers ($P < .001$), angiotensin-converting enzyme inhibitors ($P = .016$), oral nitrates ($P < .001$), and aspirin ($P < .001$). Those not treated with statins had a higher incidence of digitalis ($P < .001$) or diuretic use ($P = .001$, Table 3).

The percentage of patients experiencing 30-day morbidity was significantly less in the statin-treated group (5.9% vs 8.3%, $P < .05$). Statin-treated patients also experienced lower mortality in the 30-day period (2.5% vs 5.6%, $P < .05$; Figure 1).

Risk-adjusted outcomes also demonstrated that statin-treated patients experienced lower odds of operative mortality and morbidity. This was true for the standard risk-adjusted model (adjusted for age, sex, body surface area, smoking, previous MI, cerebrovascular and peripheral vascular disease, diabetes, ejection fraction, New York Heart Association functional class, hypertension, β-adrenergic blocker use, aspirin use, use of intra-aortic balloon pump, and operative category), with an odds ratio of 0.55 (95% confidence interval [CI], 0.32-0.93) for mortality and 0.76 (95% CI, 0.62-0.94) for morbidity. Similar results were seen after matching patients on treatment propensity scores, with an odds ratio of 0.51 (95% CI, 0.27-0.94) for mortality and 0.71 (95% CI, 0.5500.92) for morbidity (Figure 2). Primary cause of death for both statin treated and not treated groups are shown in Figure 3.

CABG or CABG with valve procedures accounted for approximately 80% of the sample (n = 3113), whereas 20% underwent valve repair or replacement only (n = 716). Univariate analysis demonstrated that 30-day mortality was higher in the valve-only group (7.5% vs 2.0%, $P < .001$). Statin use was less common in the valve-only group (7% vs 32%, $P = .002$). This necessitated controlling for operative category in the risk-adjusted analysis. In addition, the percentage of valve-only patients experiencing mortality was lower for statin-treated patients (1.96% vs 7.5%). This was not statistically significant, likely a result of the reduction in power caused by the reduced sample size.

**Discussion**

Despite advances in surgical techniques, hemodynamic monitoring, and postoperative care, cardiac surgical procedures still incur significant morbidity and mortality. Furthermore, a complicated postoperative course will result in a significant medical cost burden. Accordingly, the development of strategies to further reduce morbidity and mortality associated with cardiac surgical procedures would be of significant clinical import. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have demonstrated efficacy in the reduction of cardiovascular events in primary and secondary prevention in varied patient populations, including surgical populations.

**TABLE 3. Use of preoperative medications**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Not treated (n = 2785)</th>
<th>Statin treated (n = 1044)</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-Adrenergic blockers, %</td>
<td>44.11</td>
<td>61.69</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Digitalis, %</td>
<td>18.87</td>
<td>11.57</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Calcium antagonists, %</td>
<td>28.98</td>
<td>32.02</td>
<td>.067</td>
</tr>
<tr>
<td>Angiotensin-converting enzyme inhibitors, %</td>
<td>28.08</td>
<td>32.05</td>
<td>.016</td>
</tr>
<tr>
<td>Oral nitrates, %</td>
<td>38.07</td>
<td>55.11</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Use of diuretics, %</td>
<td>35.01</td>
<td>29.45</td>
<td>.001</td>
</tr>
<tr>
<td>Use of aspirin, %</td>
<td>55.28</td>
<td>73.93</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

**Figure 1.** Unadjusted percentages of 30-day morbidity and mortality for patients pretreated with statins (n = 1044) or not treated (n = 2785). *$P < .05$ versus not treated.

**Figure 2.** Comparison on odds ratios for unadjusted, adjusted, and propensity-matched models. The solid points represent the odds ratio, and the lines represent the 95% confidence interval. All of the odds ratios fall below the null value of 1, indicating a significantly reduced risk of 30-day mortality and morbidity outcome for patients pretreated with statins ($P < .05$ vs not treated).
The goal of the present study was to evaluate whether statin pretreatment exerted an independent effect on 30-day morbidity and mortality in a cohort of patients undergoing cardiac procedures requiring cardiopulmonary bypass. The unique and important findings of this study were that preoperative statin use was independently associated with an approximately 40% reduction in 30-day mortality, and an effect of similar but lesser magnitude was observed with a composite morbidity measure encompassing postoperative MI, stroke, cerebral bleed, embolism, or other neurologic event; pulmonary edema; infection, any systemic or organ infection (ie, sepsis, sternal or wound, subacute bacterial endocarditis, or cellulitis); renal, renal failure, dialysis, or both; vascular, peripheral (arterial circulation) disorder, such as embolic event or circulatory dysfunction; other, cause other than those listed above, accidental, trauma, multiple organ failure, or other surgical intervention that led to patient’s death.

It is becoming increasingly clear that statins have pleiotropic effects independent of lipid lowering that could result in a reduction of adverse postoperative events. These effects include the ability to improve endothelial function, decrease vasoconstriction, suppress the inflammatory response, and reduce thrombosis. In the present study there was a high incidence of patients undergoing cardiac surgical procedures who had preexisting comorbid conditions, such as diabetes, hypertension, and hypercholesterolemia. Thus these patients have preexisting endothelial dysfunction, have increased levels of circulating inflammatory markers, and are more prone to vasoconstriction and thrombosis, which in turn results in these patients being at greater operative risk. Notably, the incidence of these comorbid conditions was significantly higher in the statin-pretreated group. However, despite the increased risk conferred by these concomitant disease states, the statin-pretreated group still experienced reduced acute morbidity and mortality. It has been established that statins exert cardioprotective effects in high-risk groups. For example, statins have demonstrated efficacy in reducing rates of cardiovascular events in diabetic patients, irrespective of their initial cholesterol levels. In addition, statins have been shown to exert even more powerful and positive effects on the endothelium in diabetic patients than in healthy control subjects. The present study was retrospective and therefore could not define the mechanisms behind the observed effects of statins on postsurgical morbidity and mortality. Nevertheless, the results of this study provide the fundamental basis for future studies designed to elucidate the possible mechanisms behind these effects.

Numerous large clinical trials have conclusively demonstrated that statin treatment reduces the risk of cardiovascular events for both primary and secondary prevention. Both animal models and observational studies have shown that...
The increased use of these medications is likely due to the greater observed rate of previous MI observed in the statin-pretreated group. In large observational studies both β-adrenergic blockers and aspirin have demonstrated a survival benefit in patients undergoing CABG. Accordingly, we adjusted for the use of these medications in our analysis. Statin pretreatment still exhibited an independent association with reduced postsurgical morbidity and mortality. However, it is possible that the higher rates of cardioprotective medications seen in the statin-treated group might indicate these patients were better prepared for surgical intervention and received more preoperative care than the non–statin-treated group. It has been demonstrated that a patient cohort with increased use of the combination of statins, aspirin, and β-adrenergic receptor blockers after a coronary event had fewer recurrent MIs and lower rates of cardiac mortality.

Future studies that model the potential additive effects, synergistic effects, or both of statins with other medications would be warranted.

Although the present study clearly demonstrated the positive effect of statin treatment, the necessary dosing regimen to establish these effects has yet to be established. A small observational study demonstrated that short-term statin therapy (3–5 days) preoperatively has been associated with reduced cardiovascular adverse events after CABG. In addition, statins have shown rapid effects on both endothelial function and inflammatory markers, producing changes in as little as 24 hours to 1 week. Further studies are necessary to define the optimal temporal window for statin pretreatment before cardiac procedures. Another consideration in the present study is that although 2 statistical methods were used to control for potential confounding variables, there might be unmeasured covariates that are influencing the association seen between statin pretreatment and morbidity and mortality outcomes. Only prospective randomization can ensure (on average) that there are no systematic differences in covariates. We could not use that strategy because of the retrospective nature of this study. However, the propensity score methodology used allows a quasirandomization, which should result in unbiased estimates of the treatment effect.

Two questions that remain unanswered by this study are whether the statin-treated group met target levels of LDL control and whether there were significant differences in LDL levels between the groups. If no significant differences existed, this would contribute further evidence that the demonstrated beneficial effects of statins in this study were due to pleiotropic effects. Unfortunately, preoperative levels of LDL were not recorded in each group, and thus whether a significant difference in LDL levels existed between the groups cannot be determined.

These limitations notwithstanding, the present study provides direct evidence that statin pretreatment before cardiac...
surgical procedures imparts a beneficial effect with regard to reduced rates of acute morbidity and mortality. Our data provide a foundation for prospective studies evaluating the optimal statin regimen to initiate before cardiac procedures.

References